Stockscreener 앱 받기
4.49%
시간 외 거래:
Amgen Inc 주식(AMGN)의 최신 뉴스
The Truth About Amgen Inc.: Is This Quiet Biotech Giant Your Next Power Move? - AD HOC NEWS
Amgen’s Stock Is Already Up 14% in 2026: Why Analysts Expect $440 - TIKR.com
Twin Capital Management Inc. Sells 5,541 Shares of Amgen Inc. $AMGN - MarketBeat
Renaissance Group LLC Lowers Position in Amgen Inc. $AMGN - MarketBeat
SBI Securities Co. Ltd. Has $977,000 Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen (NASDAQ:AMGN) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
P/E Ratio Insights for Amgen - Benzinga
Amgen (AMGN) Sees Target Price Increase by Argus Research | AMGN Stock News - GuruFocus
CVS Caremark Replaces Amgen And Eli Lilly's Branded Drugs, Expands Biosimilar Strategy For Weak Bone Disorder - Benzinga
Argus Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
Amgen Advances Xaluritamig Into Early-Stage Trial for Hard-to-Treat Ewing Sarcoma - TipRanks
Amgen (AMGN) Target Price Raised by Guggenheim Analyst | AMGN St - GuruFocus
Amgen (NASDAQ:AMGN) Price Target Raised to $347.00 - MarketBeat
Guggenheim Adjusts Price Target on Amgen to $347 From $305, Maintains Neutral Rating - marketscreener.com
Amgen (NASDAQ:AMGN) Price Target Raised to $295.00 - MarketBeat
Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating - marketscreener.com
Aurdan Capital Management LLC Sells 5,316 Shares of Amgen Inc. $AMGN - MarketBeat
3,190 Shares in Amgen Inc. $AMGN Acquired by ABN AMRO Bank N.V. - MarketBeat
Biotechnology Market Set to Witness Significant Growth by 2026-2033 | Amgen Inc., GlaxoSmithKline - EIN News
Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management - GlobeNewswire Inc.
Cancer Supportive Care Drugs Market Is Going to Boom | Amgen Inc., - openPR.com
Amgen Refocuses Portfolio As Eczema Exit And Tavneos Review Raise Questions - Yahoo Finance
CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists - marketscreener.com
CVS Health to drop Amgen and Lilly’s bone disease treatments from some drug lists - WKZO
Key facts: Amgen's stock soars 8% on strong earnings; CVS to drop Prolia - tradingview.com
RBC Lifts Amgen (AMGN) Target After Strong Q4, Cites Key Drug Momentum - Finviz
CVS Health to swap Amgen and Lilly’s bone drugs with biosimilars in commercial formularies - Seeking Alpha
Amgen’s IMLYGIC Safety Study in Melanoma Reaches Completion: What Investors Should Watch - TipRanks
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Pfizer (PFE) and Merck & Company (MRK) - The Globe and Mail
Amgen Benefits From US Biosimilar Monopoly With $700m Sales For Pavblu - Citeline News & Insights
Why is Amgen stock falling premarket? - MSN
Why Is Amgen Stock Falling Premarket? - Stocktwits
BI Asset Management Fondsmaeglerselskab A S Grows Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Envestnet Asset Management Inc. - MarketBeat
Jones Financial Companies Lllp Has $10.89 Million Holdings in Amgen Inc. $AMGN - MarketBeat
Bank of America Maintains Underperform on Amgen Inc (AMGN) Feb 2026 - Meyka
Is It Time To Reassess Amgen (AMGN) After Strong Recent Share Price Gains - Yahoo Finance
Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open - TechStock²
Amgen Earnings Call: Broad Growth Amid Manageable Risks - TipRanks
Amgen (AMGN) Surges on Q4 Earnings Beat, Leading Dow Gains - GuruFocus
US FDA Review Team Split On Amgen’s Tavneos Years Before Withdrawal Request - Citeline News & Insights
Asking Amgen to withdraw Tavneos, FDA revisits years-old data issue - BioCentury
Amgen (AMGN) Stock Hits 52-Week Highs: Buy Signal? - Finviz
Amgen Seen Driving Long-Term Growth on R&D Pipeline, Oppenheimer Says - marketscreener.com
Amgen stock price jumps as earnings beat puts MariTide obesity bet back in focus - TechStock²
Amgen climbs 8% after upbeat earnings report - breakingthenews.net
Deep Dive Into Amgen Stock: Analyst Perspectives (14 Ratings) - Benzinga
BofA Securities reiterates Underperform rating on Amgen stock at $304 - Investing.com
Amgen Inc (AMGN) Stock Price Up 7.36% on Feb 4 - GuruFocus
Cantor Fitzgerald Raises Price Target for Amgen (AMGN) to $350 | - GuruFocus
Amgen thumbs-down on FDA’s ask, Tavneos sales continue - BioWorld MedTech
Cantor Fitzgerald Increases Amgen (NASDAQ:AMGN) Price Target to $350.00 - MarketBeat
Amgen’s FORTITUDE-301 Cancer Trial Completion: What Investors Should Watch in Bemarituzumab’s Next Act - TipRanks
Amgen Inc. (NASDAQ:AMGN) Q4 2025 earnings call transcript - MSN
Cantor Fitzgerald raises Amgen stock price target to $350 on strong earnings - Investing.com
Why Amgen Stock Is Paying Off Big For Long-Term Investors - Forbes
Leerink Partners Adjusts Price Target on Amgen to $355 From $305, Maintains Market Perform Rating - marketscreener.com
AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus - TradingView
Amgen (NASDAQ:AMGN) Sets New 1-Year High Following Strong Earnings - MarketBeat
Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan - BioPharma Dive
Amgen's Diversified Portfolio and Growing Cardiovascular Focus Support a Wide Moat - morningstar.com
Amgen stock reaches all-time high of $353.74 By Investing.com - Investing.com Canada
Amgen stock reaches all-time high of $353.74 - Investing.com
Morgan Stanley Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
The Goldman Sachs Group Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price - MarketBeat
Royal Bank Of Canada Forecasts Strong Price Appreciation for Amgen (NASDAQ:AMGN) Stock - MarketBeat
Amgen stock price target raised to $360 from $335 at RBC Capital - Investing.com
Leerink Partners Raises Amgen (AMGN) Price Target to $355 | AMGN Stock News - GuruFocus
Street View: Amgen banks on pipeline depth and long term weight-loss play - TradingView
Amgen (NASDAQ:AMGN) Price Target Raised to $355.00 - MarketBeat
Amgen Fell 4% Last Week. Here’s Where the Stock Could Head in 2026 - TIKR.com
Amgen Inc. (NASDAQ:AMGN) Q4 2025 Earnings Call Transcript - Insider Monkey
9.92%
자본화:
|
볼륨(24시간):